Yan Leyfman: Episode 3 of The Translational Edge on Cancer Anticoagulation Is Now Live on Shuf
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared Jeremy Bellaiche‘s post on LinkedIn, adding:
“Episode 3 of The Translational Edge is now live on Shuf.
As oncology care becomes more personalized, one critical question remains:
Are we dosing based on evidence—or outdated assumptions?
This episode explores the evolving science of anticoagulation in cancer patients with obesity—and how aligning practice with data can directly impact outcomes.
Translating breakthroughs into impact.
Jeremy Bellaiche, Founder of Shuf, shared a post on LinkedIn:
“Excited to share the episode 3 of The Translational Edge season 2 with Yan Leyfman exclusively on Shuf !
Treating Blood Clots in Cancer Patients with Obesity: Why Dosing Finally Caught Up with Reality.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy